StockWatch
·

Suven Pharmaceuticals Ltd Q3 FY26 Results

COHANCEQ3 FY26 Results
Filing
MetricValue ( Cr)Q2 FY26Q3 FY25
Revenue544.552.0%77.3%
Total Income550.713.6%70.6%
Expenditure505.253.7%137.1%
PBT40.6051.5%63.0%
Net Profit29.0256.3%65.2%
OPM16.62%5.15pp6.28pp
NPM5.27%6.35pp20.53pp
EPS0.9650.5%70.5%
View full financials

Informational and educational content only. Not investment advice.